SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Baker Bros. Advisors (GP) LLC (Last) (First) (Middle) 667 MADISION AVENUE 21ST FLOOR (Street) NEW YORK NY US 10065 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/01/2013	3. Issuer Name and Ticker or Trading Symbol SYNAGEVA BIOPHARMA CORP [ GEVA ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Remarks: On July 1, 2013, a Certificate of Conversion was filed with the State of Delaware to convert Baker Bros. Advisors, LLC from a limited liability company into a limited partnership named Baker Bros. Advisors LP (the "Adviser"), with Baker Bros. Advisors (GP) LLC (the "Adviser GP") as the Adviser's sole general partner. As the Adviser previously reported on its Form 4 filed on June 10, 2013, the Adviser and, collectively, therefore, its general partner have voting and dispositive power over securities held by its clients Baker Brothers Life Sciences, L.P., 14159, L.P., 667, L.P., Baker Bros. Investments II, L.P., Baker Bros. Investments, L.P., Baker Biotech Fund II(A), L.P., and Baker Tisch Investments, L.P. (the "Funds"), but neither the Adviser nor the Adviser GP have a pecuniary interest in such securities, as the Adviser may only receive a portion of the asset-based management fee. Julian C. Baker and Felix J. Baker each may be deemed to control the Adviser GP. For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, Baker Bros. Advisors (GP) LLC is deemed a director by deputization by virtue of its representation on the Board of Directors of Synageva Biopharma Corp.

No securities are beneficially owned.

	BAKER BROS. ADVISORS (GP), LLC Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing	07/11/2013
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.